Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

Literature DB >> 21220617

Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

Katarzyna D Chmiel¹, Dan Suan, Christopher Liddle, Brian Nankivell, Ramy Ibrahim, Charmaine Bautista, John Thompson, David Fulcher, Richard Kefford.

Abstract

Entities: Chemical Disease

Mesh：

Substances：

Year: 2011 PMID： 21220617 DOI： 10.1200/JCO.2010.32.2206

Source DB: PubMed Journal: J Clin Oncol ISSN： 0732-183X Impact factor: 44.544

Keyword Cloud
Cited

× No keyword cloud information.

37 in total

1. Kidney injuries related to ipilimumab.

Authors: Hassane Izzedine; Victor Gueutin; Chems Gharbi; Christine Mateus; Caroline Robert; Emilie Routier; Marina Thomas; Alain Baumelou; Philippe Rouvier
Journal: Invest New Drugs Date: 2014-04-01 Impact factor: 3.850

2. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy.

Authors: Tauqeer Ahmed; Ritwik Pandey; Bhavini Shah; Jason Black
Journal: BMJ Case Rep Date: 2015-07-14

Review 3. Immune checkpoint inhibitors in melanoma.

Authors: Adam J Cooper; Matteo S Carlino; Richard F Kefford
Journal: Melanoma Manag Date: 2015-08-10

4. Ipilimumab: its potential in non-small cell lung cancer.

Authors: Pascale Tomasini; Nataliya Khobta; Laurent Greillier; Fabrice Barlesi
Journal: Ther Adv Med Oncol Date: 2012-03 Impact factor: 8.168

Review 5. Checkpoint Inhibitors.

Authors: Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal: Dtsch Arztebl Int Date: 2019-02-22 Impact factor: 5.594

Resolution of severe ipilimumab-induced hepatitis after antithymocyte globulin therapy.

1. Kidney injuries related to ipilimumab.

2. Resolution of ipilimumab induced severe hepatotoxicity with triple immunosuppressants therapy.

Review 3. Immune checkpoint inhibitors in melanoma.

4. Ipilimumab: its potential in non-small cell lung cancer.

Review 5. Checkpoint Inhibitors.

Review 6. Toxicities Associated With PD-1/PD-L1 Blockade.

Review 7. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.

Review 8. Moving towards personalized treatments of immune-related adverse events.

Review 9. Ipilimumab and its toxicities: a multidisciplinary approach.

10. Ipilimumab associated hepatitis: imaging and clinicopathologic findings.